反义寡核苷酸jacifusen治疗FUS-ALS:一项研究者发起的多中心开放标签病例系列
该扩展获取项目通过五家中心(美国四家医院、瑞士一家)的单患者临床试验性新药申请,纳入12例FUS变异携带者,接受鞘内注射jacifusen 2.8至33.9个月。最常见不良事件为背痛(6例,50%)、头痛(4例,33%)、恶心(3例,25%)和腰穿后头痛(3例,25%);2例死亡被认为与试验药物无关。脑脊液NfL浓度在治疗6个月后最多降低82.8%,大多数参与者ALSFRS-R功能仍持续下降,但1例在10个月后出现客观功能恢复,另1例保持无症状且肌电图异常改善。
要点
- jacifusen鞘内注射在12例FUS-ALS参与者中总体安全,最常见不良事件为背痛(6例,50%)。
- 脑脊液NfL浓度在治疗6个月后最多降低82.8%,提示可能减少轴索损伤。
- 大多数参与者ALSFRS-R功能仍持续下降,但1例在10个月后出现客观功能恢复。
核心结论
- 研究结果提示jacifusen治疗FUS-ALS具有安全性和可能的疗效。
- jacifusen的疗效正在一项正在进行的临床试验中进一步评估。
研究设计与样本
- 该扩展获取项目通过单患者临床试验性新药申请在五家中心开展,包括美国四家医院和瑞士一家。
- 纳入携带FUS变异且有运动神经元病起病临床证据或电生理异常(若未诊断为ALS)的参与者,排除长期气管造口通气的患者。
- 参与者序贯入组,接受系列鞘内注射jacifusen,治疗持续2.8至33.9个月。
- 基于从20 mg至120 mg的多次递增剂量,随着安全性和其他数据的获取,后续方案被修改,最后入组的参与者从治疗开始即接受每月120 mg剂量。
- 安全性采用不良事件通用术语标准第4.0版和标准脑脊液指标评估。
主要发现
- 2019年6月11日至2023年6月2日期间,共招募12例参与者,中位年龄26岁(范围16-45),其中女性7例(58%)、男性5例(42%)。
- 脑脊液细胞计数或总蛋白浓度短暂升高见于6例(50%)参与者,与治疗持续时间无关。
- 最常见不良事件为背痛(6例,50%)、头痛(4例,33%)、恶心(3例,25%)和腰穿后头痛(3例,25%)。
- 项目期间记录到2例参与者死亡,均被认为与试验药物无关。
- 脑脊液NfL浓度在治疗6个月后最多降低82.8%;大多数参与者ALSFRS-R功能仍持续下降,但1例在10个月后出现前所未有的客观功能恢复,另1例保持无症状且肌电图异常有记录改善。
关键数值与推荐
- 不良事件通用术语标准第4.0版用于安全性评估。
- 脑脊液NfL浓度作为轴索损伤和神经退行性变的生物标志物。
- ALSFRS-R评分作为运动功能的总体测量指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathogenic variants of fused in sarcoma (FUS) cause amyotrophic lateral sclerosis (FUS-ALS), with evidence of gain of function. Jacifusen is an antisense oligonucleotide targeting FUS pre-mRNA, previously shown to delay neurodegeneration in a mouse model and potentially slow functional decline in a first-in-human study. Here, we sought to further evaluate use of jacifusen as a treatment for FUS-ALS. METHODS: This expanded access programme was conducted through a series of single-patient investigational new drug applications at five sites (four hospitals in the USA and one in Switzerland). Participants carried a FUS variant and had clinical evidence of motor neuron disease onset or electrophysiological abnormalities, if not a diagnosis of ALS. Participants were ineligible if chronically ventilated with tracheostomy. Enrolled sequentially, participants received serial intrathecal injections of jacifusen over 2·8-33·9 months. Based on multiple ascending doses of jacifusen (from 20 mg to 120 mg), successive protocols were modified as safety and other data were acquired, with the last participants enrolled receiving 120 mg doses monthly from the start of their treatment. Safety was assessed using the Common Terminology Criteria for Adverse Events version 4.0 and standard cerebrospinal fluid (CSF) metrics. Concentration of neurofilament light chain (NfL) in CSF was used as a biomarker of axonal injury and neurodegeneration, and the ALS Functional Rating Scale-Revised (ALSFRS-R) score was used as an overall measure of motor function. Biochemical analysis and immunohistochemical staining were done on post-mortem CNS tissues to quantify FUS protein expression and assess the burden of FUS pathology. FINDINGS: Between June 11, 2019, and June 2, 2023, we recruited 12 participants (median age 26 years [range 16-45]; seven [58%] were female and five [42%] were male) into the expanded access programme. Transient elevations in cell counts or total protein concentration in CSF (six [50%] participants) were unrelated to treatment duration. The most common adverse events were back pain (six [50%]), headache (four [33%]), nausea (three [25%]), and post-lumbar puncture headache (three [25%]). Two participant deaths were recorded during the programme, both thought to be unrelated to the investigational drug. The concentration of NfL in CSF was reduced by up to 82·8% after 6 months of treatment. Although most participants had continued functional decline (as measured by ALSFRS-R) after starting treatment with jacifusen, one showed unprecedented, objective functional recovery after 10 months, and another remained asymptomatic, with documented improvement in electromyographic abnormalities. Biochemical and immunohistochemical analysis of CNS tissue samples from four participants showed reduced FUS protein levels and an apparent decrease in the burden of FUS pathology. INTERPRETATION: The findings suggest the safety and possible efficacy of jacifusen for treating FUS-ALS. The efficacy of jacifusen is being further evaluated in an ongoing clinical trial. FUNDING: ALS Association, Project ALS, Ionis Pharmaceuticals, Tow Foundation, Nancy D Perlman and Thomas D Klingenstein Innovation Fund for Neurodegenerative Disease, National Institutes of Health, Angel Fund for ALS Research, Cellucci Fund for ALS Research, Max Rosenfeld ALS Fund, University of Minnesota, and the Muscular Dystrophy Association.
引用
- Shneider NA, Harms MB, Korobeynikov VA, et al. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet. 2025. PMID: 40414239. doi:10.1016/S0140-6736(25)00513-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。